STAT+: Eli Lilly warns hospitals to submit claims data in the next five days or lose their 340B drug discounts

STAT PlusPharmalot Eli Lilly warns hospitals to submit claims data in the next five days or lose their 340B drug discounts Drugmakers are trying to reduce what they call duplicate discounts paid to hospitals in the federal program Manage alerts for this article Email this article Share this article By Ed SilvermanJune 1, 2026 Pharmalot Columnist, Senior Writer Ed Silverman[email protected]Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation and legislation. He is also the author of the morning Pharmalittle newsletter and the afternoon Pharmalot newsletter. Eli Lilly has told about 50 hospitals participating in a federal drug discount program to submit comprehensive claims data over the next five days or they will no longer receive the mandated price breaks. The move comes after the company announced a policy last January demanding such data in a bid to reduce what it calls duplicate discounts paid to participating hospitals. The issue has riled the pharmaceutical industry and contributed to a long-standing clash with hospitals over the 340B drug discount program.Advertisement For the past few years, more than 2,300 hospitals have complied with the demand, but some of the larger hospitals systems around the U.S. have refused to do so, despite recent follow-up letters regarding the policy that went into effect on Feb. 1, according to Derek Asay, senior vice president for government strategy and federal accounts at Lilly. Up to 1,000 have so far not complied. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? Log in Monthly $39 Totals $468 per year $39/month Get Started Totals $468 per year Starter $30 for 3 months, then $399/year $30 for 3 months Get Started Then $399/year Annual $399 Save 15% $399/year Get Started Save 15% 11+ Users Custom Savings start at 25%! Request A Quote Request A Quote Savings start at 25%! 2-10 Users $300 Annually per user $300/year Get Started $300 Annually per user View All Plans To read the rest of this story subscribe to STAT+. Subscribe Log In drug pricing, Pharmaceuticals, Policy, STAT+ Submit a correction requestReprints Ed Silverman Pharmalot Columnist, Senior Writer Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation and legislation. He is also the author of the morning Pharmalittle newsletter and the afternoon Pharmalot newsletter. Newsletter From the lab to the medicine chest, these are the must-read drug industry updates of the day Recommended Pharmalot June 1, 2026 STAT Plus: Pharmalittle: We’re reading about pancreatic and lung cancer drugs, China biotech growth, and more May 29, 2026 STAT Plus: Pharmalittle: We’re reading about Replimune drug getting third try at FDA approval, a Pfizer deal in China, and more Advertisement Pharmalot May 29, 2026 STAT Plus: Up and down the ladder: The latest comings and goings Pharmalot May 28, 2026 STAT Plus: Pharmalittle: We’re reading about a hepatitis B drug, CVS returns Lilly obesity drug to formularies, and more Pharmalot May 27, 2026 STAT Plus: Pharmalittle: We’re reading about an AstraZeneca breast cancer pill, an ADAP deal in Florida, and more Subscriber Picks